Janus Capital Management Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Janus Capital Management reduced its stake in Amgen by 21.65% during the most recent quarter end. The investment management company now holds a total of 7,565,906 shares of Amgen which is valued at $1,309,053,056 after selling 2,090,117 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Amgen makes up approximately 1.07% of Janus Capital Management’s portfolio.

Other Hedge Funds, Including , Wespac Advisors Socal boosted its stake in AMGN in the latest quarter, The investment management firm added 9,450 additional shares and now holds a total of 26,445 shares of Amgen which is valued at $4,575,514. Amgen makes up approx 2.88% of Wespac Advisors Socal’s portfolio.Trust Investment Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 8,675 shares of Amgen which is valued at $1,495,830. Amgen makes up approx 1.66% of Trust Investment Advisors’s portfolio.Uss Investment Management Ltd boosted its stake in AMGN in the latest quarter, The investment management firm added 4,600 additional shares and now holds a total of 68,300 shares of Amgen which is valued at $11,845,269. Amgen makes up approx 0.20% of Uss Investment Management Ltd’s portfolio. Ariel Capital Advisors added AMGN to its portfolio by purchasing 12,553 company shares during the most recent quarter which is valued at $2,142,546. Amgen makes up approx 1.30% of Ariel Capital Advisors’s portfolio.

Amgen closed down -0.46 points or -0.27% at $171.51 with 25,12,225 shares getting traded on Monday. Post opening the session at $172.37, the shares hit an intraday low of $171.1201 and an intraday high of $172.5 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.